These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 37421779)
1. Intralymphatic injection of chemotherapy drugs modulated with glucose improves their anticancer effect. Sukhbaatar A; Mori S; Shiga K; Kodama T Biomed Pharmacother; 2023 Sep; 165():115110. PubMed ID: 37421779 [TBL] [Abstract][Full Text] [Related]
2. Study of the physicochemical properties of drugs suitable for administration using a lymphatic drug delivery system. Fukumura R; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T Cancer Sci; 2021 May; 112(5):1735-1745. PubMed ID: 33629407 [TBL] [Abstract][Full Text] [Related]
3. Docetaxel administered through a novel lymphatic drug delivery system (LDDS) improved treatment outcomes for lymph node metastasis. Sukhbaatar A; Mori S; Sugiura T; Kodama T Biomed Pharmacother; 2024 Feb; 171():116085. PubMed ID: 38171241 [TBL] [Abstract][Full Text] [Related]
4. Drug formulation augments the therapeutic response of carboplatin administered through a lymphatic drug delivery system. Mishra R; Sukhbaatar A; Dorai A; Mori S; Shiga K; Kodama T Cancer Sci; 2023 Jan; 114(1):259-270. PubMed ID: 36168838 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model. Sora S; Sukhbaatar A; Fukushige S; Mori S; Sakamoto M; Kodama T Cancer Sci; 2023 Jan; 114(1):227-235. PubMed ID: 36056924 [TBL] [Abstract][Full Text] [Related]
6. Intranodal delivery of modified docetaxel: Innovative therapeutic method to inhibit tumor cell growth in lymph nodes. Sukhbaatar A; Mori S; Kodama T Cancer Sci; 2022 Apr; 113(4):1125-1139. PubMed ID: 35100484 [TBL] [Abstract][Full Text] [Related]
7. Optimal range of injection rates for a lymphatic drug delivery system. Fujii H; Horie S; Takeda K; Mori S; Kodama T J Biophotonics; 2018 Aug; 11(8):e201700401. PubMed ID: 29461015 [TBL] [Abstract][Full Text] [Related]
8. Optimization of the delivery of molecules into lymph nodes using a lymphatic drug delivery system with ultrasound. Kato S; Yoshiba S; Mori S; Kodama T Int J Pharm; 2021 Mar; 597():120324. PubMed ID: 33540016 [TBL] [Abstract][Full Text] [Related]
9. Intranodal pressure of a metastatic lymph node reflects the response to lymphatic drug delivery system. Kato S; Takeda K; Sukhbaatar A; Sakamoto M; Mori S; Shiga K; Kodama T Cancer Sci; 2020 Nov; 111(11):4232-4241. PubMed ID: 32882076 [TBL] [Abstract][Full Text] [Related]
10. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. Fujii H; Horie S; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T Cancer Med; 2019 May; 8(5):2241-2251. PubMed ID: 30945479 [TBL] [Abstract][Full Text] [Related]
11. Protocols for the Evaluation of a Lymphatic Drug Delivery System Combined with Bioluminescence to Treat Metastatic Lymph Nodes. Sukhbaatar A; Kodama T Methods Mol Biol; 2022; 2524():333-346. PubMed ID: 35821485 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false-negative metastatic lymph nodes. Tada A; Horie S; Mori S; Kodama T Cancer Sci; 2017 Nov; 108(11):2115-2121. PubMed ID: 28846190 [TBL] [Abstract][Full Text] [Related]
13. Direct delivery of a cytotoxic anticancer agent into the metastatic lymph node using nano/microbubbles and ultrasound. Sato T; Mori S; Sakamoto M; Arai Y; Kodama T PLoS One; 2015; 10(4):e0123619. PubMed ID: 25897663 [TBL] [Abstract][Full Text] [Related]
14. New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network. Kodama T; Matsuki D; Tada A; Takeda K; Mori S Sci Rep; 2016 Sep; 6():32506. PubMed ID: 27581921 [TBL] [Abstract][Full Text] [Related]
15. A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer. Yang Q; Wang XD; Chen J; Tian CX; Li HJ; Chen YJ; Lv Q Tumour Biol; 2012 Dec; 33(6):2341-8. PubMed ID: 22948779 [TBL] [Abstract][Full Text] [Related]
16. Study on enhanced lymphatic exposure of polyamidoamin-alkali blue dendrimer for paclitaxel delivery and influence of the osmotic pressure on the lymphatic targeting. Yang R; Mao Y; Ye T; Xia S; Wang S; Wang S Drug Deliv; 2016 Sep; 23(7):2617-2629. PubMed ID: 26017243 [TBL] [Abstract][Full Text] [Related]
18. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503 [TBL] [Abstract][Full Text] [Related]
19. A combination of lymphatic drug delivery of anti-CTLA-4 antibody and local radiotherapy for solid-tumor treatment. Takagi K; Sukhbaatar A; Inaba Y; Mori S; Kodama T Cancer Sci; 2024 Oct; ():. PubMed ID: 39380185 [TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives. Lan HR; Zhang YN; Han YJ; Yao SY; Yang MX; Xu XG; Mou XZ; Jin KT J Nanobiotechnology; 2023 Aug; 21(1):247. PubMed ID: 37528366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]